Jiangsu Aims for Over 20 Brain-Computer Interface Products to Secure Medical Device Approval by 2030

Deep News
Mar 10

On March 10, the Jiangsu Provincial Department of Industry and Information Technology and eight other departments jointly released the "Jiangsu Province Brain-Computer Interface Industry Innovation and Development Action Plan." The plan calls for promoting the establishment of clinical trial environments for brain-computer interface technologies in top-tier hospitals within the province. It encourages clinical research related to brain-computer interface implants and supports eligible institutions in providing corresponding clinical diagnosis and treatment services. Key medical institutions are urged to open clinical settings to enterprises, universities, and research institutes, setting up specialized brain-computer interface research wards to meet needs such as product development, data collection, and clinical trials. The plan also emphasizes strengthening pre-registration guidance for related medical devices, supporting priority entry into special review procedures, and facilitating the inclusion of eligible products in the innovative medical device catalog. Additionally, community hospitals and organizations for persons with disabilities are encouraged to accelerate the application of these technologies in early screening for brain diseases, predictive diagnosis, and assisting the elderly and individuals with disabilities. By 2030, the initiative aims to have no fewer than 20 brain-computer interface products approved through medical device registration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10